A team of researchers at Cornell University has developed a new biodegradable vascular graft that could transform the treatment of cardiovascular disease, the leading cause of death worldwide. Anova Biomedical co-founders Prof. Yadong Wang, biomedical engineering, and Anthony D’Amato, a postdoctoral associate in biological engineering and the chief executive officer of Anova Biomedical, have developed a metallo-elastomer that mimics the natural elasticity of arteries and veins. This innovation allows Anova to improve the current vascular graft technology, which only applies to vessels larger than five millimeters. “Every year, between end-stage renal disease and cardiovascular diseases, there are millions of people suffering and dying,” D’Amato said. “There isn’t a viable treatment…